The UCLA Immunogenetics Center (UIC) provides state-of-the-art Histocompatibility and Immunogenetics testing for solid organ and stem cell transplantation, pre- and post-transplant immune assessment and testing for diagnosis of diseases with associations to the Human Leukocyte Antigens (HLA). As one of the first established laboratories in Histocompatibility and Immunogenetics, we continue to advance the field through research, clinical innovation, proficiency testing and educational training. UIC provides customized testing and support services for clinical trials and clinical research to monitor response to experimental therapy.
The UIC is a nationally recognized reference laboratory for Histocompatibility and Immunogenetics testing and is licensed by the States of California, New York, Maryland, Pennsylvania and Rhode Island, and is CMS certified and accredited by the American Society for Histocompatibility and Immunogenetics (ASHI).
Goals and Mission
- Leading Through Quality: Provide the highest standard of Immunogenetics, Histocompatibility and Transplantation Immunology testing and interpretation to the patients we serve.
- Leading Through Research: Advance the understanding of Immunogenetics and Transplantation Immunology through innovative basic and clinical research.
- Leading Through Development: Be the forefront of development of new technologies and reference materials to improve the quality of patient care.
- Leading Through Training: Training the next generation of leaders in Histocompatibility and Immunogenetics to navigate the complexities of testing and research in Transplantation Immunology.
- Now Recruiting For UCLA Histocompatibility Director Training Program. Applications are being accepted for the Director In Training Position to start July of every academic year.
- Recruitment: Dr. Rebecca Sosa, PhD was recruited as new Assistant Professor in the Department of Pathology and Laboratory Medicine and Assistant Director of the UCLA Immunogenetics Center.
- Butler CL, Hickey MJ, Jiang N, Zheng Y, Gjertson D, Zhang Q, Rao P, Fishbein GA, Cadeiras M, Deng MC, Banchs HL, Torre G, DeNofrio D, Eisen HJ, Kobashigawa J, Starling RC, Kfoury A, Van Bakel A, Ewald G, Balazs I, Baas AS, Cruz D, Ardehali R, Biniwale R, Kwon M, Ardehali A, Nsair A, Ray B, Reed EF. Discovery of non-HLA antibodies associated with cardiac allograft rejection and development and validation of a non-HLA antigen multiplex panel: From bench to bedside. Am J Transplant, 2020
- Sosa RA, Rossetti M, Naini BV, Groysberg VM, Kaldas FM, Busuttil RW, Chang YL, Gjertson DW, Kupiec-Weglinski JW, Reed EF. Pattern Recognition Receptor-reactivity Screening of Liver Transplant Patients: Potential for Personalized and Precise Organ Matching to Reduce Risks of Ischemia-reperfusion Injury. Ann Surg. 2020
- Geer LI, Kagele S, Townshend S, Watson B, Reed EF, Hickey MJ. Design of a state of the art reporting system and process improvement for reporting of high complexity single antigen bead data for transplant patients electronic medical record. BMJ Open Qual. 2020
- Greenshields AL, Jollet I, Liwski RS, Taupin JL, Valenzuela NM. Abolishing serum interference in detection of HLA antibodies: Who, How, When and Why? Hum Immunol. 2019
- Yin Y, Reed EF, Zhang Q. Integrate CRISPR/Cas9 for protein expression of HLA-B*38:68Q via precise gene editing. Sci Rep. 2019